MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


SMALL-CAP WINNERS & LOSERS: Solvonis gets US patent; Liontrust falls

ALN

The following stocks are the leading risers and fallers among London Main Market small-caps on Wednesday.

----------

SMALL-CAP - WINNERS

----------

Panther Metals PLC, up 17% at 74.76 pence, 12-month range 110.00p-36.00p. The London-based mineral deposits explorer appoints Extrakt Process Solutions LLC to conduct phased metallurgical testwork for the recovery of metals from the Winston tailings project in Ontario, Canada. ‘We are delighted to have the opportunity to appoint Extrakt Process Solutions who are pioneering advanced non-cyanide mineral processing technologies to recover metals from tailings in an environmentally sustainable manner,’ says Chief Executive Officer Darren Hazelwood.

----------

Solvonis Therapeutics PLC, up 1.1% at 0.31p, 12-month range 0.40p-0.11p. The biopharmaceutical company, focused on central nervous system disorders, gets notice of allowance from the US Patent and Trademark Officer for a series of compounds within its proprietary SVN-SDN-14 post-traumatic stress disorder discovery programme. It says one compound from this series is currently being evaluated alongside other candidates, and the firm expects to select a lead compound in the first quarter of 2026. ‘This patent allowance strengthens both the scientific and commercial foundations of our PTSD programme. It reflects our strategy of combining rigorous neuroscience with disciplined medicinal chemistry to build differentiated, scalable CNS therapeutics,’ says Chief Executive Officer Anthony Tennyson.

----------

SMALL-CAP - LOSERS

----------

Liontrust Asset Management PLC, down 2.0% at 241.50p, 12-month range 478.00p-237.21p. The London-based fund manager continues to fall after Deutsche Bank Research cut its rating on the stock to ’sell’ from ’hold’ on Tuesday. It lowers its price target for the stock to 175p from 250p.

----------

Copyright 2026 Alliance News Ltd. All Rights Reserved.